Polyamine Metabolites as Biomarkers in Head and Neck Cancer Biofluids.
Brian C DeFelice1, Oliver Fiehn1, Peter Belafsky2
1West Coast Metabolomics Center, University of California, Davis, CA 95616, USA.
Diagnostics (Basel, Switzerland)
|April 23, 2022
Summary
Researchers found distinct polyamine metabolite levels in the urine and saliva of head and neck cancer (HNC) patients. These findings suggest polyamine metabolites could serve as novel, non-invasive biomarkers for early HNC detection.
Area of Science:
- Oncology
- Metabolomics
- Biomarker Discovery
Background:
- Head and neck cancer (HNC) diagnosis urgently requires novel, non-invasive biomarkers for early intervention.
- Elevated polyamine metabolites are linked to various cancers and poorer prognoses.
Purpose of the Study:
- To assess polyamine metabolite concentrations in saliva and urine of HNC patients compared to healthy controls.
Main Methods:
- Targeted metabolomic analysis using quantitative liquid chromatography-mass spectrometry.
- Analysis of saliva and urine samples from 39 HNC patients and 89 healthy controls.
Main Results:
- Significantly different concentrations of N1-acetylspermine (ASP), N8-acetylspermidine (ASD), and N1,N12-diacetylspermine (DAS) were found in HNC patient urine.
- Elevated levels of ASP were detected in the saliva of HNC patients compared to controls.
Conclusions:
- Polyamine-based metabolite biomarkers in saliva and urine show promise for HNC diagnostics.
- Further investigation into these biomarkers is warranted for potential clinical application in HNC detection.
